CN104774782A - 鸡源粪肠球菌分离株及其应用 - Google Patents
鸡源粪肠球菌分离株及其应用 Download PDFInfo
- Publication number
- CN104774782A CN104774782A CN201410817717.5A CN201410817717A CN104774782A CN 104774782 A CN104774782 A CN 104774782A CN 201410817717 A CN201410817717 A CN 201410817717A CN 104774782 A CN104774782 A CN 104774782A
- Authority
- CN
- China
- Prior art keywords
- mdxef
- chicken
- strain
- enterococcus faecalis
- bacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000194032 Enterococcus faecalis Species 0.000 title claims abstract description 29
- 229940032049 enterococcus faecalis Drugs 0.000 title claims abstract description 28
- 241000287828 Gallus gallus Species 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 26
- 238000004321 preservation Methods 0.000 claims abstract description 8
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 4
- 229960005486 vaccine Drugs 0.000 claims abstract description 4
- 230000000813 microbial effect Effects 0.000 claims abstract description 3
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 241000186779 Listeria monocytogenes Species 0.000 claims description 4
- 241000606856 Pasteurella multocida Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 229940051027 pasteurella multocida Drugs 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 3
- 230000032258 transport Effects 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 85
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 abstract description 22
- 108010053775 Nisin Proteins 0.000 abstract description 22
- 239000004309 nisin Substances 0.000 abstract description 22
- 235000010297 nisin Nutrition 0.000 abstract description 22
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 14
- 230000000845 anti-microbial effect Effects 0.000 abstract description 8
- 238000001228 spectrum Methods 0.000 abstract description 8
- 235000014655 lactic acid Nutrition 0.000 abstract description 7
- 239000002253 acid Substances 0.000 abstract description 5
- 210000004534 cecum Anatomy 0.000 abstract description 4
- 229940099352 cholate Drugs 0.000 abstract description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract description 4
- 239000003242 anti bacterial agent Substances 0.000 abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 239000004310 lactic acid Substances 0.000 abstract description 3
- 244000144977 poultry Species 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 238000000855 fermentation Methods 0.000 abstract description 2
- 230000004151 fermentation Effects 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 239000003674 animal food additive Substances 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 description 25
- 239000007788 liquid Substances 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 16
- 235000015097 nutrients Nutrition 0.000 description 16
- 244000057717 Streptococcus lactis Species 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 210000000941 bile Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 150000002460 imidazoles Chemical class 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- -1 Glaxo) Chemical compound 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000005611 electricity Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229940049547 paraxin Drugs 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 239000003833 bile salt Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 241000252983 Caecum Species 0.000 description 3
- 241000194031 Enterococcus faecium Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- 241000223932 Eimeria tenella Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229960003376 levofloxacin Drugs 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 229940081561 rocephin Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 2
- KTAVBOYXMBQFGR-MAODNAKNSA-J tetrasodium;(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-1-oxidoethylidene]amino]-3-[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C KTAVBOYXMBQFGR-MAODNAKNSA-J 0.000 description 2
- 150000004684 trihydrates Chemical class 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 229960001572 vancomycin hydrochloride Drugs 0.000 description 2
- LCTORFDMHNKUSG-XTTLPDOESA-N vancomycin monohydrochloride Chemical compound Cl.O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 LCTORFDMHNKUSG-XTTLPDOESA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014889 Enterococcal infections Diseases 0.000 description 1
- 241001491366 Euphydryas colon Species 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 241000385740 bacterium 37 Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了鸡源粪肠球菌分离株及其应用。本发明从20周龄健康鸡盲肠中分离得到一株性能优异的粪肠球菌分离株B10,其微生物保藏编号为:CCTCC No:M2014488,分类命名为MDXEF-1。该分离株有优异的耐酸性能和耐胆盐性能,抑菌谱广,对常见致病菌均有明显的抑制作用;分离株MDXEF-1对多种抗生素敏感,将该菌饲喂给肉仔鸡后可以显著增加鸡的体重,促进鸡的生长,能够作为促进禽类生长的饲料添加剂。本发明分离株MDXEF-1可以作为宿主菌而且在不外加nisin诱导物的情况下高效表达异源蛋白,适宜于生产中大规模发酵应用,能作为饲用乳酸菌疫苗运送载体。
Description
技术领域
本发明涉及粪肠球菌菌株,尤其涉及鸡源粪肠球菌(Enterococcus faecalis)分离株,本发明还涉及该分离株在禽类养殖、表达外源蛋白以及作为饲用乳酸菌疫苗运送载体等方面的应用,属于粪肠球菌菌株的分离及其应用领域。
背景技术
乳酸菌是人及动物肠道内一类重要的优势益生菌,无毒副作用的乳酸菌微生态制剂近年来受到了广泛关注。肠球菌属在1984年被列为独立的新菌属。粪肠球菌(Enterococcus faecalis)是肠球菌属内的代表种,为革兰氏阳性,过氧化氢酶阴性球菌,是人和动物肠道内主要菌群之一(Malik RK,Montecalvo MA,Reale MR,et al.Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit.Pediatr Infect Dis J,1999,18(4):352.),其能产生天然抗生素,有利于机体健康(Malik RK,Montecalvo MA,Reale MR,et al.Epidemiology and control of vancomycin-resi stant enterococci in a regional neonatal intensive care unit.Pediatr Infect Dis J,1999,18(4):352.);同时还能产生细菌素等抑菌物质,具有抑制大肠杆菌和沙门氏菌等病原菌的生长,改善肠道微环境等功能(David FM,Arthur EB,Gary JN,et al.An investigation of vancomycin-resistant enterocicci faecium within the pediatric service of a large urban medical center.Pediatr Infect Dis J,1998,17(3):184.);粪肠球菌还能抑制肠道内产尿素酶细菌和腐败菌的繁殖,减少肠道尿素酶和内毒素的含量,使血液中氨和内毒素的含量下降。
粪肠球菌(E.faecalis)作为一种肠道益生菌,在医学和食品工程领域得到广泛应用。另外,因为动物源的粪肠球菌是动物消化道内正常存在 的一类微生物,所以在肠道内具有较强的耐受胃酸和胆盐作用的特点,是一种兼性厌氧的乳酸菌,其与培养保存条件苛刻的厌氧双歧杆菌相比,更适合于在生产中应用(李光辉,肠球菌感染研究进展,国外医学内科学分册,1999,26:471)。
因此,从动物源材料中分离获得性能优良且可以作为宿主菌表达异源蛋白的鸡源粪肠球菌分离株将具有重要的实践意义。
发明内容
本发明的目的之一是提供一株耐酸和耐胆盐性能优异、抑菌谱广、无致病性、能够有效促进禽类生长、可以作为宿主菌表达异源蛋白的鸡源粪肠球菌(Enterococcus faecalis)分离株;
本发明的目的之二是将所分离的鸡源粪肠球菌分离株应用于禽类养殖、表达外源蛋白等方面。
本发明的上述目的是通过以下技术方案来实现的:
本发明首先从20周龄健康鸡盲肠中分离得到菌株共计13株,分别命名B1,B2,B3,B4,B5,B6,B7,B8,B9,B10,B11,B12,B13。
本发明将分离获得的13株菌株进行耐酸实验和耐胆盐实验。根据耐酸实验结果可见:本发明所分离的13株菌株可以耐受肠道低pH值,在pH2.0~7.0范围内可存活,pH 5.0存活率可达98.3%;其中,相比于其它的11株分离株,分离株B10以及B11的耐酸性能最为优异;根据耐胆盐实验结果可见:本发明的分离13株菌株可以耐肠道高胆盐,在胆盐浓度0.1%~0.8%范围内可存活;其中,分离菌株B6,B7,B9以及B10在0.1%胆盐培养基中的存活率超过了90%,并且在0.8%胆盐培养基中的存活率均较其它各分离株明显要高。综合耐酸实验和耐胆盐实验结果可见,分离株B10不仅具有优异的耐酸性能,还具有优异的耐胆盐性能,是在分离的13株菌株中性能最为优异的一株菌株。因此,本发明将分离株B10提交专利认可的机构进行保藏, 其微生物保藏编号为:CCTCC No:M 2014488;分类命名是:粪肠球菌MDXEF-1(Enterococcus faecalis MDXEF-1);保藏时间是:2014年10月16日;保藏单位是:中国典型培养物保藏中心;保藏地址是:中国武汉武汉大学。
本发明将耐酸和耐胆盐性能优异的分离株B10(MDXEF-1)进行抑菌谱测定;抑菌谱测定结果表明,分离株B10对常见致病菌(如大肠埃希氏菌,鸡白痢沙门氏菌,多杀性巴氏杆菌,单增李斯特菌,金黄色葡萄球菌等)均具有明显的抑制作用。
本发明通过实验进一步发现,分离株B10对多种抗生素敏感,将该菌饲喂给肉仔鸡后,与正常饲喂组相比,可以显著增加鸡的体重,因此,可以将本发明分离株B10掺入到鸡等禽类的饲料中用于促进禽类的生长。
本发明通过检测发现,分离株B10粪肠球菌菌株中不合有质粒。将含有鸡柔嫩艾美尔球虫(Eimeria tenella)3-1E基因的大肠杆菌-乳酸菌穿梭表达质粒pTX8048-3-1E电转化入MDXEF-1中筛选获得重组菌pTX8048-3-1E/MDXEF-1,重组菌经乳链球菌素(nisin)诱导后,采用Westernblot方法成功检测到了目的蛋白表达。此外,更为重要的是,实验中发现重组菌pTX8048-3-1E/MDXEF-1在不加nisin诱导情况下也可表达外源蛋白,而且重组乳酸乳球菌pTX8048-3-1E/L.lactis NZ9000经MDXEF-1菌培养液上清诱导后可以表达目的蛋白,初步表明MDXEF-1为产nisin菌株。
综上,本发明从健康鸡盲肠中分离得到具有优异的耐酸性能和耐胆盐性能的粪肠球菌分离株B10,该菌株对常见致病菌(如大肠埃希氏菌,鸡白痢沙门氏菌,多杀性巴氏杆菌,单增李斯特菌,金黄色葡萄球菌等)均具有明显的抑制作用,抑菌谱广;分离株B10可以作为饲料添加剂促进禽类的生长。此外,本发明分离株B10可以作为宿主菌而且在不外加nisin诱导物的情况下表达异源蛋白,适宜于生产中大规模发酵应用,因此能够作 为饲用乳酸菌疫苗运送载体。
附图说明
图1分离株B10革兰氏染色形态(×100)。
图2MDXEF-1菌株16s rDNA PCR扩增产物电泳图;1.DNA Marker DL5000;2~8.16s rDNA扩增片段;9.PCR阴性对照。
图3阳性质粒pTX8048-3-1E图谱(Ma DX,Gao MY,Rami AD et al.,Parasitol.Res.,2013,112:4161~4167)。
图4重组阳性菌pTX8048-3-1E/MDXEF-1PCR鉴定结果;1DNA Marker DL5000;2-9PCR扩增阳性质粒中3-1E片段。
图5Westernblot检测目的蛋白3-1E在粪肠球菌MDXEF-1表达结果;1.预染蛋白分子量标准;2.MDXEF-1菌对照;3.未诱导重组菌pTX8048-3-1E/MDXEF-1;4.Nisin诱导重组菌pTX8048-3-1E/MDXEF-1;5.Nisin诱导空载体重组菌pTX8048/MDXEF-1。
图6Westemblot检测MDXEF-1菌培养上清中nisin;1.MDXEF-1菌阴性对照;2.pTX8048-3-1E/L.lactis NZ9000经5ng/ml nisin诱导的菌体蛋白;3.pTX8048-3-1E/L.lactis NZ9000经MDXEF-1菌培养上清诱导的菌体蛋白;4.pTX8048-3-1E/L.lactis NZ9000不经外源诱导物(nisin)诱导的菌体蛋白阴性对照;5.预染蛋白分子量标准。
图7重组菌pTX8048-3-1E/MDXEF-1免疫后血清中IgG变化。
具体实施方式
下面结合具体实施例来进一步描述本发明,本发明的优点和特点将会随着描述而更为清楚。但是应理解所述实施例仅是范例性的,不对本发明的范围构成任何限制。本领域技术人员应该理解的是,在不偏离本发明的精神和范围下可以对本发明技术方案的细节和形式进行修改或替换,但这 些修改或替换均落入本发明的保护范围。
实施例1鸡源乳酸菌分离株的分离
无菌取20周龄健康鸡盲肠内容物,加入适量磷酸盐缓冲液(PBS,pH7.2),震荡混匀后10倍系列稀释(10-1~10-8),每个稀释度取50ul分别涂布于MRS固体培养基平板(MRS培养基购自北京陆桥生物技术有限公司,培养基成分包括:牛肉蛋白粉,鱼肉汁,酵母浸出汁粉,葡萄糖,醋酸钠,柠檬酸二铵,吐温80,硫酸镁,硫酸锰),37℃厌氧培养。挑取MRS平板上生长的单菌落,划板传代培养。经革兰氏染色镜检,过氧化氢酶实验,初步从健康20周龄健康鸡盲肠中分离到共计13株菌株,暂命名为B1,B2,B3,B4,B5,B6,B7,B8,B9,B10,B11,B12,B13。
实验例1鸡源乳酸菌分离株耐酸实验和耐胆盐实验
1耐酸实验
将MRS液体培养基pH值分别调节为pH 2.0,pH 2.5,pH 3.0,pH 3.5,pH 4.0,pH 4.5,pH 5.0,pH 6.0,pH 7.0,以2%比例接种实施例1得到的各分离株(B1~13)的菌液于5ml MRS液体培养基中,37℃培养3h。计算不同酸性条件下各分离菌株的存活数,即将培养3h后的菌液在MRS液体培养基中十倍梯度稀释,涂布MRS培养平板,置于37℃静止培养24h,进行菌落形成单位(CFU)计数,以pH6.0培养液中的活菌数为对照,计算各分离株在不同pH值培养液中存活数,计算出相对于pH6.0培养液菌数的存活率。
实验结果表明,所分离的13株菌株在培养基pH值自2.0向6.0逐渐增高时,菌株存活率呈逐渐升高趋势,在培养基pH值为7时的存活率又开始下降。其中,相比于其它的11株分离株,分离株B10以及B11的耐酸性能最为优异(表1)。
表1不同pH值条件下各分离株相对pH6培养液中的存活率
2耐胆盐实验
将MRS液体培养基中的牛胆盐(购自Sigma公司)浓度分别调节为0%,0.1%,0.2%,0.4%,0.6%,0.8%,培养液pH值调节为6.0。以2%比例接种活化的分离株菌液,37℃静止培养5h。菌液在MRS培养液中十倍梯度稀释,涂MRS平板,置于37℃静止培养24h后进行平板菌落形成单位(CFU)计数,以无胆盐MRS培养基中活菌数为对照,计算不同胆盐浓度下分离菌的存活率。
实验结果表明,分离菌株B6,B7,B9以及B10在0.1%胆盐培养基中的存活率超过了90%,并在0.8%胆盐培养基中的存活率均较其它各分离株明显要高,其中,B10菌株的存活率显著高于其它菌株的存活率(表2)。
表2不同胆盐浓度培养基中分离株存活率
实验例2分离株B10的生物学性能测定实验
1、分离株B10抑菌谱测定实验
本实验选取耐酸和耐胆盐性能具有较好的分离株B10进行抑菌谱测定。
将活化的指示菌,即大肠埃希氏菌(C83552),鸡白痢沙门氏菌(C79-13),多杀性巴氏杆菌(C48102),单核细胞增生李氏杆菌(C53005),金黄色葡萄球菌2086以2%比例分别接种于各自LB液体培养基中培养过夜。各指示菌液经10倍系列稀释后,分别涂布于LB培养平板,测定五种菌的菌落形成单位(CFU)。将各指示菌约1×108CFU菌数(0.1ml)分别涂布于等距离安放4个牛津杯(内径约6mm)的LB平板上,取B10培养12h的上清液体,5000rpm离心20min,去除沉淀,上清调pH值至3.0。将上述上清液200μl加入各个平板的3个牛津杯中,另一个牛津杯中加乳酸(pH3.0)作为观察对照,37℃培养12h。测量牛津杯周围出现的抑菌圈直径(mm),试验进行三次重复,计算抑菌圈均值。
分离株B10对五种指示菌抑制作用见表3。
表3分离株B10抑菌谱测定
2分离株B10形态观察
对筛选到的具有较好耐酸、耐胆盐及抑菌性能的分离株B10进行革兰氏 染色。B10菌经MRS平板培养24h,菌落呈圆形,边缘光滑,灰白色,直径约0.5mm。在洁净载玻片上滴加100ul无菌生理盐水,用吊菌环从平板上挑取单菌落并与灭菌生理盐水混匀,自然干燥后进行革兰氏染色,即草酸铵结晶紫染液(A液结晶紫2g,95%乙醇20ml;B液草酸铵0.8g,蒸馏水80ml,混合A、B液后室温放置48h)染色1min,流水冲洗;之后滴加卢氏碘液(碘化钾2g溶解于少量蒸馏水中,碘片1g溶解于碘化钾溶液中,碘片全部溶解后加蒸馏水至300ml)染1min;水洗,吸水纸吸去水分;滴加95%乙醇并轻摇约0.5min,,蕃红染液(蕃红2.5g溶解于100ml 95%乙醇)复染1min,镜检。
镜检结果显示,分离菌B10为革兰氏阳性,球菌,不形成芽孢(图1)。
3分离株B10药物敏感试验
应用常规方法进行药敏试验,配置MRS琼脂培养平板,将1×108CFU菌数(0.1ml)的B10菌液用玻璃涂棒均匀涂布在平板表面,静止放置5min,待平板表面干燥后,将含抗生素(青霉素G,头孢噻吩钠,氯霉素,卡那霉素,头孢三嗪,红霉素,左氧氟沙星,环丙沙星,盐酸万古霉素,磺胺嘧啶SD,阿莫西林,盐酸四环素)的药敏纸片放置在平板表面,灭菌玻璃棒轻压使药敏片平整并紧密贴附在培养基表面。37℃培养24h,测量抑菌圈直径。
实验结果显示,、B10菌对青霉素G,氯霉素,卡那霉素,左氧氟沙星,环丙沙星,磺胺嘧啶SD,阿莫西林以及盐酸四环素均敏感;对头孢塞吩钠,头孢三嗪,红霉素,盐酸万古霉素耐药(表4)。
表4B10分离株药物敏感测定
416s rDNA鉴定B10分离株
提取B10菌的基因组DNA(参照Bioteke公司试剂盒说明进行),提取DNA保存于-20℃备用。应用16srDNA扩增通用引物(上游5′-AGAGTTTGATCCTGGCTCA-3′,下游5′-AAGGAGGTGATCCAGCCGC-3′)进行PCR扩增16s rDNA片段,PCR扩增体系为,10×Ex Taq Buffer 2.5ul,Ex Taq DNA聚合酶0.25ul,dNTP 2ul,通用引物上游0.5ul,通用引物下游0.5ul,DNA模板0.5ul,ddH2O 18.75ul,总体系25ul,PCR扩增条件为,94℃2min,94℃30s,51.2℃30s,72℃30s,72℃10min。经1%琼脂糖凝胶电泳检测,可见1500左右的目的条带(图2)。
目的条带经琼脂糖凝胶回收试剂盒(宝生物工程(大连)有限公司)回收纯化,克隆入pMD18-T载体中,筛选出阳性克隆质粒后送上海生工生物工程公司进行序列测定,序列经BLAST序列比对分析,结果表明,该菌为粪肠球菌(Enterococcus faecalis),将B10分离株命名为MDXEF-1,并于2014年10月保存于中国典型培养物保藏中心(CCTCC),保藏编号为NO:M2014488。
实验例3MDXEF-1菌(B10分离株)致病性检测实验
将20只5日龄SPF雏鸡随机分成4组,即MDXEF-1菌腹腔注射组,MDXEF-1菌滴鼻组,MDXEF-1菌肌肉注射组和空白对照组。将1×109CFU的MDXEF-1菌分别经腹腔注射途径、滴鼻途径、腿部肌肉注射途径接种。自接种后24h连续观察雏鸡临床症状。接种后第3天将各组鸡处死进行病理解剖学观察,同时采取各脏器(肝脏,肺脏,心脏,脾脏,肾脏,肌肉)材料于10%福尔马林中固定,常规方法进行病理组织学切片和苏木素-伊红染色,之后显微镜下进行观察。剖检观察同时,自肝脏、肺脏、脾脏、心脏血液和腿部肌肉用吊菌环吊菌接种于GM17培养基中培养过夜,观察是否有细 菌生长。
实验结果显示,各组鸡接种后24h均未表现出任何临床症状,病理解剖学观察也未见各脏器出现眼观可见的病理学变化,病理组织学观察见各脏器组织结构与正常组相比无明显变化,各脏器实质和间质细胞无明显损伤。自肝脏、肺脏、脾脏、心脏血液和腿部肌肉吊菌接种的培养基中未见细菌生长。结果表明,MDXEF-1菌经上述剂量和上述接种途径接种后对鸡无致病性。
实验例4MDXEF-1菌促进雏鸡增重的实验
60只1日龄SPF雏鸡无菌饲养,3日龄剔除体重过大和过小的雏鸡,将选用的45只雏鸡平均分成3组,即MDXEF-1组(饲喂MDXEF-1菌),正常饲喂对照组,L.lactisNZ9000组(饲喂L.lactis NZ9000菌),每组15只鸡。各组鸡自由采食,在5,6,7日龄,15,16,17日龄,25,26,27日龄,每天灌服剂量为1×108CFU菌夜(0.1ml),28日龄对各组鸡进行称重,比较各组鸡体重变化(表5)。
统计结果表明,MDXEF-1组与L.lactis NZ9000组差异显著(p<0.05),MDXEF-1组与空白对照组相比差异极显著(p<0.01)。结果显示,分离菌株MDXEF-1饲喂雏鸡后可以显著增加体重。
表5分离株MDXEF-1口服饲喂雏鸡后增重变化
注:肩标大写字母不同表示差异极显著(p<0.01),肩标小写字母不同表示差异显著(p<0.05)
实验例5MDXEF-1菌作为宿主菌表达异源蛋白的实验
1.MDXEF-1菌的质粒检测
自MRS平板上挑取单菌落接种至MRS液体培养基中,静止培养过夜。 按2%接种量转接到100ml新鲜MRS液体培养基中,培养过夜,采用质粒大量提取试剂盒(生工生物工程(上海)股份有限公司)提取质粒,用以检测MDXEF-1菌中是否携带质粒。
经1%琼脂糖凝胶电泳显示MDXEF-1中无质粒存在。
2.MDXEF-1菌作为宿主菌表达异源蛋白
2.1MDXEF-1菌感受态细胞制备方法
从新鲜GM17(M17培养基加入5g/L葡萄糖即为GM17,M17培养基购自北京陆桥生物技术有限公司,培养基成分为:多聚蛋白胨,植物蛋白胨,牛肉膏,酵母膏,β-磷酸甘油二钠,抗坏血酸,MgSO4·7H2O,乳糖)琼脂平板上挑取MDXEF-1单菌落,接种于5ml GM17液体培养基中,37℃培养过夜;按2%接种量转接到100ml新鲜SGGM17液体培养基中,37℃静置培养至OD600值为0.4;培养物置于冰上15min,6000rpm 4℃离心10min,收集细胞;转化缓冲液(0.5mol/L蔗糖,10%甘油)洗涤细胞,6000rpm,4℃离心10min;重复上述步骤一次;去除上清液,收集沉淀,向菌体细胞中加入1%体积培养物的转化缓冲液,将菌体悬起,分装1.5mL Eppendorf管,-80℃保存。
2.2重组阳性粪肠球菌pTX8048-3-1E/MDXEF-1制备
取干净的电转化杯,紫外线下灭菌30min,冰上预冷10min;取100ul冰冻的感受态细胞悬浮液,加入5ul乳酸菌表达质粒pTX8048-3-1E(为本发明人构建并保存,启动子为PnisA,氯霉素抗性标记,阳性质粒图谱见图3,详细构建方法参见发明人发表文献(Ma DX,Gao MY,Rami AD et al.,Parasitol.Res.,2013,112:4161~4167),混匀冰浴10min;转移混合液至电转化杯。设置转化电压为2000V,快速擦干电转化杯,放入电击槽中,进行电击转化;向转化后的电转化杯中加入890ul GM17MC恢复培养液(M17培养基,5g/L葡萄糖,20mmol/L MgCl2,2mmol/L CaCl2);将液体移入 Eppendorf管中,37℃静止培养3h,将细胞涂布于含有3ug/mL氯霉素的GM17固体平板上,37℃培养48h。选取疑似阳性菌落8个,于含有10ug/ml氯霉素GM17培养液中培养过夜,次日采用试剂盒(宝生物工程公司)提取质粒,进行PCR鉴定,以提取的8个质粒作为模板可扩增出500bp目的条带(图4)。
2.3重组阳性乳酸菌pTX8048-3-1E/MDXEF-1表达蛋白检测
将鉴定为阳性的目的重组菌pTX8048-3-1E/MDXEF-1按2%比例接至新鲜20ml GM17培养基(10ug/ml氯霉素)。OD值为0.4时加10ng/ml乳酸链球菌素(nisin)(Sigma,USA)诱导剂。诱导8h后将20ml菌液于4℃,10000rpm,离心10min。取沉淀进行如下处理,用PBS重悬沉淀,4℃8000rpm离心5min,重复洗涤三次,400ul PBS重悬沉淀,超声处理,每次8s,间隔10s,共8次。超声处理后样品加入等体积上样缓冲液(含Tris-HCl,SDS,溴酚兰,甘油,β巯基乙醇),沸水浴10min,-20℃保存备用。
蛋白样品经聚丙烯酰胺凝胶电泳(SDS-PAGE)电泳分离,之后将凝胶中的蛋白电转移到硝酸纤维素膜上,采用1∶400稀释的兔抗3-1E蛋白抗体(为本发明人实验室制备保存,可参见发明人发表文献Ma DX,Ma CL,Pan L et al.,Experimental parasitology,2011,127(1):208-14.)孵育2h,TTBS液(Tris-HCl 20mmol/L,pH 7.5,NaCl 100mmol/L,0.1%Tween-20)洗涤3次,每次5min。之后加入1∶1000稀释的辣根过氧化物酶标记的羊抗兔IgG抗体(Sigma,USA),孵育2h。TBS液(Tris-HCl 20mmol/L,pH 7.5,NaCl100mmol/L)洗涤2次,每次5min,DAB显色,westernblot检测表达蛋白结果见图5。试验中设立MDXEF-1菌对照,未诱导重组菌pTX8048-3-1E/MDXEF-1对照,nisin诱导空载体重组菌pTX8048/MDXEF-1对照。
3.MDXEF-1菌产nisin检测
鉴于上述未诱导重组菌pTX8048-3-1E/MDXEF-1同样检测到了目的蛋 白的表达,因此推测MDXEF-1菌可以产生nisin。为了鉴定MDXEF-1是否可以产生nisin,采用本发明人实验室先前构建并保存的重组菌pTX8048-3-1E/L.lactis NZ9000来鉴定(重组菌pTX8048-3-1E/L.lactis NZ9000可构建参考文献Ma DX,Gao MY,Rami AD et al.,Parasitol Res.,2013,112:4161~4167,质粒pTX8048-3-1E中启动子为PnisA,重组菌pTX8048-3-1E/L.lactis NZ9000需在nisin诱导下才能表达目的蛋白)。将MDXEF-1菌于GM17培养基中37℃培养过夜,5000×g离心10min,收集上清,将MDXEF-1菌的培养上清1000倍稀释后加入到OD值为0.5的重组菌pTX8048-3-1E/L.lactis NZ9000培养液中,即以MDXEF-1菌培养上清代替nisin诱导物。同时以MDXEF-1空菌和不加外源诱导物的重组菌pTX8048-3-1E/L.lactis NZ9000作为阴性对照,以加5ng/ml nisin诱导重组菌pTX8048-3-1E/L.lactis NZ9000作为阳性对照(参见Ma DX,Gao MY,Rami AD,Parasitol Res,2013,112:4161~4167)。继续培养3h后,进行SDS-PAGE电泳,之后采用westernblot检测pTX8048-3-1E/L.lactis NZ9000中目的蛋白表达,westernblot具体操作方法同上。
实验结果表明,MDXEF-1菌培养上清含有nisin,可以代替nisin诱导重组菌pTX8048-3-1E/L.lactis NZ9000表达目的蛋白(图6)。表明MDXEF-1菌可以产生nisin。
实验例6MDXEF-1菌作为宿主菌表达蛋白的应用
1、实验方法
1日龄SPF雏鸡80只,无球虫条件下自由采食饮水。随机分成3组,即PBS缓冲液组、pTX8048-3-1E/MDXEF-1组、pTX8048/MDXEF-1组,每组25羽。每次免疫前进行称重并记录。免疫用菌和菌体样品制备、SDS-PAGE及Western blot鉴定的具体方法同前述。免疫程序为,在5~7、15~17、25~27日龄pTX8048-3-1E/MDXEF-1组每只鸡口服1×108CFU(0.1 ml)重组阳性菌pTX8048-3-1E/MDXEF-1,pTX8048/MDXEF-1组每只鸡口服1×108CFU(0.1ml)重组阳性菌pTX8048/MDXEF-1,PBS组口服0.1ml PBS缓冲液(pH7.2),免疫三次。28日龄对各组鸡进行称重,经翅静脉采血制备血清,检测血清中IgG抗体变化。
3-1E蛋白纯化
采用镍柱(Invitrogen)纯化大肠杆菌表达3-1E目的蛋白作为包被抗原(携带pET30a-3-1E质粒的阳性大肠杆菌为本发明人实验室构建保存,可参见Ma DX,Ma CL,Pan L et al.,Experimental parasitology,2011,127(1):208-14.),检测具体步骤如下:将1ml填料加入新柱子中,让液体流出,加入2ml蒸馏水洗涤一次。蒸馏水2ml重复洗涤一次,加入2ml lysis Buffer(与超声相同浓度咪唑)洗涤一次。待纯化蛋白上柱,封口膜封口,室温振摇结合2h。梯度洗脱程序为:2ml 20mM咪唑洗一次,除去未结合蛋白。2ml 30mM咪唑洗2次,除去杂蛋白。2ml 40mM咪唑洗2次,除去杂蛋白。2ml 50mM咪唑洗1次,除去杂蛋白。2ml100mM咪唑洗1次,除去杂蛋白。2ml 250mM咪唑洗4次,洗脱目的蛋白。蒸馏水封柱。
间接ELISA检测抗体
纯化后3-1E蛋白适当稀释,ELISA板每孔包被100μl。4℃过夜。每孔加入200μl PBST,洗涤5min,重复三次。每孔加入200ul 3%BSA封闭,37℃孵育2h。每孔加入200μl PBST洗涤,重复三次,每次5min。每孔加入100μl待测血清抗体(稀释度为1∶50),37℃孵育1h。每孔加入200μl PBST,洗涤三次,每次5min。每孔加入100μl鼠抗鸡IgG抗体(1∶1000),37℃孵育1h。每孔加入200μl PBST洗涤,重复三次,每次5min。每孔加入100μl TMB显色液显色15min。每孔加入2M硫酸终止显色。酶标仪检测OD450吸光值。
2、实验结果
检测结果见图7。结果显示,重组菌pTX8048-3-1E/MDXEF-1第一次口服免后未检测到3-1E蛋白特异性抗体,但第二次和第三次免疫后可观察到高于其他二组的特异性抗体水平(p<0.05)。不同小写字母表示组间差异显著(p<0.05)。
Claims (7)
1.一株鸡源粪肠球菌(Enterococcus faecalis)分离株MDXEF-1,其特征在于:其微生物保藏编号为:CCTCC No:M 2014488。
2.权利要求1所述的鸡源粪肠球菌分离株在制备抑制致病性细菌的动物饲料或饲料添加剂中的用途。
3.按照权利要求2所述的用途,其特征在于:所述的致病性细菌包括大肠埃希氏菌,鸡白痢沙门氏菌,多杀性巴氏杆菌,单增李斯特菌或金黄色葡萄球菌。
4.权利要求1所述的鸡源粪肠球菌分离株在促进动物生长中的用途。
5.按照权利要求4所述的用途,其特征在于:所述的动物是禽类;优选为鸡。
6.权利要求1所述的鸡源粪肠球菌分离株在作为宿主菌株表达外源蛋白中的用途。
7.权利要求1所述的鸡源粪肠球菌分离株作为饲用乳酸菌疫苗运送载体的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410817717.5A CN104774782B (zh) | 2014-12-25 | 2014-12-25 | 鸡源粪肠球菌分离株及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410817717.5A CN104774782B (zh) | 2014-12-25 | 2014-12-25 | 鸡源粪肠球菌分离株及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104774782A true CN104774782A (zh) | 2015-07-15 |
CN104774782B CN104774782B (zh) | 2017-12-19 |
Family
ID=53616558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410817717.5A Expired - Fee Related CN104774782B (zh) | 2014-12-25 | 2014-12-25 | 鸡源粪肠球菌分离株及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104774782B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106167785A (zh) * | 2016-08-29 | 2016-11-30 | 内蒙古工业大学 | 一种粪肠球菌菌株及其应用 |
CN107988095A (zh) * | 2017-11-27 | 2018-05-04 | 华中农业大学 | 一种高效降解四环素类抗生素的微生物菌剂及应用 |
CN108517347A (zh) * | 2018-04-12 | 2018-09-11 | 江南大学 | 一种Bacteroides cellulosilyticus的筛选培养基及其应用 |
CN111088194A (zh) * | 2020-01-16 | 2020-05-01 | 无锡拜弗德生物科技有限公司 | 一株粪肠球菌及其应用 |
CN115838664A (zh) * | 2021-05-19 | 2023-03-24 | 湖南农业大学 | 一种培养粪肠球菌mg 2108的液体培养基 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101220342A (zh) * | 2007-11-14 | 2008-07-16 | 大连三仪动物药品有限公司 | Fq15粪肠球菌以及采用该菌种生产促生长饲料添加剂的方法 |
CN102031235A (zh) * | 2010-11-09 | 2011-04-27 | 中国农业大学 | 一种粪肠球菌anse228及其应用 |
CN102816788A (zh) * | 2012-08-23 | 2012-12-12 | 东北农业大学 | 一种在乳酸乳球菌中表达鸡堆型艾美耳球虫3-1e蛋白的方法 |
CN103074281A (zh) * | 2013-01-21 | 2013-05-01 | 黑龙江八一农垦大学 | 一株粪肠球菌fjl19及其应用 |
-
2014
- 2014-12-25 CN CN201410817717.5A patent/CN104774782B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101220342A (zh) * | 2007-11-14 | 2008-07-16 | 大连三仪动物药品有限公司 | Fq15粪肠球菌以及采用该菌种生产促生长饲料添加剂的方法 |
CN102031235A (zh) * | 2010-11-09 | 2011-04-27 | 中国农业大学 | 一种粪肠球菌anse228及其应用 |
CN102816788A (zh) * | 2012-08-23 | 2012-12-12 | 东北农业大学 | 一种在乳酸乳球菌中表达鸡堆型艾美耳球虫3-1e蛋白的方法 |
CN103074281A (zh) * | 2013-01-21 | 2013-05-01 | 黑龙江八一农垦大学 | 一株粪肠球菌fjl19及其应用 |
Non-Patent Citations (1)
Title |
---|
AHMED ST.等: "Effects of Bacillus amyloliquefaciens as a probiotic strain on growth performance,cecal microflora,and fecal noxious gas emissions of broiler chickens.", 《POULT SCI.》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106167785A (zh) * | 2016-08-29 | 2016-11-30 | 内蒙古工业大学 | 一种粪肠球菌菌株及其应用 |
CN106167785B (zh) * | 2016-08-29 | 2019-05-28 | 内蒙古工业大学 | 一种粪肠球菌菌株及其应用 |
CN107988095A (zh) * | 2017-11-27 | 2018-05-04 | 华中农业大学 | 一种高效降解四环素类抗生素的微生物菌剂及应用 |
CN107988095B (zh) * | 2017-11-27 | 2020-06-02 | 华中农业大学 | 一种高效降解四环素类抗生素的微生物菌剂及应用 |
CN108517347A (zh) * | 2018-04-12 | 2018-09-11 | 江南大学 | 一种Bacteroides cellulosilyticus的筛选培养基及其应用 |
CN111088194A (zh) * | 2020-01-16 | 2020-05-01 | 无锡拜弗德生物科技有限公司 | 一株粪肠球菌及其应用 |
CN115838664A (zh) * | 2021-05-19 | 2023-03-24 | 湖南农业大学 | 一种培养粪肠球菌mg 2108的液体培养基 |
Also Published As
Publication number | Publication date |
---|---|
CN104774782B (zh) | 2017-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rajoka et al. | Isolation and evaluation of probiotic potential of lactic acid bacteria isolated from poultry intestine | |
CN102071162B (zh) | 枯草芽孢杆菌lfb112、其产生的细菌素及应用 | |
CN105176874B (zh) | 凝结芽孢杆菌fm603及其应用 | |
CN104774782A (zh) | 鸡源粪肠球菌分离株及其应用 | |
CN105175518B (zh) | 凝结芽孢杆菌fm603产生的细菌素及其制备方法 | |
CN112694992B (zh) | 一株可缓解腹泻的两歧双歧杆菌及其应用 | |
WO2023087944A1 (zh) | 一株改善肉鸡生产性能和免疫水平的乳酸片球菌及其筛选方法与应用 | |
CN110878267A (zh) | 一株唾液乳杆菌及其用途 | |
CN114231470A (zh) | 一株可缓解溃疡性结肠炎的嗜酸乳杆菌及其应用 | |
CN117844692B (zh) | 一种台湾乳杆菌及其应用 | |
CN115927206A (zh) | 一株跨种属裂解型克罗诺杆菌噬菌体及其用途 | |
Silva et al. | Evaluation of a probiotic and a competitive exclusion product inoculated in ovo on broiler chickens challenged with Salmonella Heidelberg | |
Idoui | Probiotic properties of Lactobacillus strains isolated from gizzard of local poultry | |
CN105779346A (zh) | 一种产细菌素的屎肠球菌及其应用 | |
CN105104712B (zh) | 一种微生物饲料添加剂及其制备方法 | |
EP4050095A1 (en) | Lactobacillus plantarum from breast milk and use thereof | |
CN104004697A (zh) | 一种单基因缺失粗糙型布鲁氏菌及其疫苗的生产方法 | |
CN116083277B (zh) | 具有缓解溃疡性结肠炎功效的乳酸片球菌zjuids13及其应用 | |
Khan et al. | In vitro characterization of probiotic properties and anti-Campylobacter activity of Lactobacillus spp. isolated from poultry, fermented foods and human faeces. | |
CN106389475A (zh) | 脆弱拟杆菌在预防和/或治疗脑膜炎中的应用 | |
CN109609409A (zh) | 发酵乳杆菌cqpc06及其在制备改善溃疡性结肠炎的食品或药品中的应用 | |
CN112877239B (zh) | 一株乳酸杆菌菌株及其应用 | |
CN111518724B (zh) | 格氏乳杆菌hmv18及其外泌蛋白和应用 | |
CN109161501B (zh) | 一种饲用地衣芽孢杆菌及其应用 | |
CN106615622A (zh) | 一种促进雏鸡生长及增强雏鸡抵抗鸡白痢沙门氏菌感染能力的饲料添加剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171219 |